# Longitudinal Patient Data Spain - OMOP

First published: 01/02/2024

**Last updated:** 17/10/2024

Data source

Human

Hospital outpatient visit records

**Primary care medical records** 

**Specialist ambulatory care records** 

# Administrative details

# Administrative details

#### **Data source ID**

1111151

#### Data source acronym

LPD SPA

#### **Data holder**

**IQVIA** 

## **Data source type**

Hospital outpatient visit records

Primary care medical records

Specialist ambulatory care records

## Main financial support

Funding by own institution

Funding from industry or contract research

# **Care setting**

Hospital outpatient care

Primary care - GP, community pharmacist level

Primary care - specialist level (e.g. paediatricians)

## **Data source qualification**

If the data source has successfully undergone a formal qualification process (e.g., from the EMA, ISO or other certifications), this should be described.

No

#### **Data source website**

https://www.iqvia.com/solutions/real-world-evidence/real-world-data-and-insights

# Contact details

Sarah Seager sarah.seager@iqvia.com



sarah.seager@iqvia.com

# Data source regions and languages

#### **Data source countries**

**Spain** 

#### **Data source languages**

# Data source establishment

#### **Data source established**

01/01/2006

#### **Data source time span**

First collection: 01/01/2006

The date when data started to be collected or extracted.

# **Publications**

# Data source publications

Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID -19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries. Pharmacoepidemiology and Drug Safety (2022). 10.1002/pds.5419.

Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US. BMJ 2022;379:e071594

Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS. Clin Epidemiol. 2022;14:369-384.

# **Studies**

List of studies that have been conducted using the data source

Drug Utilisation Study of conjugated oestrogens/bazedoxifene (CE/BZA) in the European Union (EU)

Drug Utilisation Study of Intuniv® (guanfacine extended release) in European Countries, Study protocol I: Database study (Intuniv data base study Europe)

# Data elements collected

# The data source contains the following information

#### **Disease information**

Does the data source collect information with a focus on a specific disease? This might be a patient registry or other similar initiatives.

No

#### Rare diseases

Are rare diseases captured? In the European Union a rare disease is one that affects no more than 5 people in 10,000.

No

## **Pregnancy and/or neonates**

Does the data source collect information on pregnant women and/or neonatal subpopulation (under 28 days of age)?

Yes

# Hospital admission and/or discharge

No

#### **ICU** admission

Cause of death	
Captured	
Cause of death	vocabulary
Not coded (Free	text)
Prescriptions o	of medicines
Captured	
Prescriptions v	ocabulary
RxNorm	
Dispensing of I	nedicines
Captured	
Dispensing voc	abulary
other	
RxNorm	
Dispensing voc	cabulary, other
CVX	
Advanced ther	apy medicinal products (ATMP)
Is information on adv	vanced therapy medicinal products included? A medicinal product for human
use that is either a g	ene therapy medicinal product, a somatic cell therapy product or a tissue
engineered products	as defined in Regulation (EC) No 1394/2007 [Reg (EC) No 1394/2007 Art 1(1)].
No	

Is information on intensive care unit admission available?

No

#### **Contraception**

Is information on the use of any type of contraception (oral, injectable, devices etc.) available?

Yes

#### Indication for use

Does the data source capture information on the therapeutic indication for the use of medicinal products?

Captured

## **Indication vocabulary**

**SNOMED** 

#### **Medical devices**

Is information on medicinal devices (e.g., pens, syringes, inhalers) available?

No

#### **Administration of vaccines**

No

#### **Procedures**

Does the data source capture information on procedures (e.g., diagnostic tests, therapeutic, surgical interventions)?

Captured

# **Procedures vocabulary**

**SNOMED** 

## **Healthcare** provider

Is information on the person providing healthcare (e.g., physician, pharmacist, specialist) available? The healthcare provider refers to individual health professionals or a health facility organisation licensed to provide health care diagnosis and treatment services including medication, surgery and medical devices.

#### **Clinical measurements**

Is information on clinical measurements (e.g., BMI, blood pressure, height) available?

Yes

#### **Genetic data**

Are data related to genotyping, genome sequencing available?

Not Captured

#### **Biomarker data**

Does the data source capture biomarker information? The term "biomarker" refers to a broad subcategory of medical signs ( objective indications of medical state observed from outside the patient), which can be measured accurately and reproducibly. For example, haematological assays, infectious disease markers or metabolomic biomarkers.

Captured

## Biomarker data vocabulary

Other

# Biomarker vocabulary, other

LOINC, SNOMED, Free text

#### **Patient-reported outcomes**

Is information on patient-reported outcomes (e.g., quality of life) available?

No

## Patient-generated data

Is patient-generated information (e.g., from wearable devices) available?

Yes

#### Units of healthcare utilisation

Are units of healthcare utilisation (e.g., number of visits to GP per year, number of hospital days) available or can they be derived? Units of healthcare utilisation refer to the quantification of the use of services for the purpose of preventing or curing health problems.

Yes

# **Unique identifier for persons**

Are patients uniquely identified in the data source?

Yes

## **Diagnostic codes**

Captured

## Diagnosis / medical event vocabulary

**SNOMED** 

# **Medicinal product information**

Captured

# Medicinal product information collected

Active ingredient(s)

Brand name

Package size

Route of administration

Strength

# **Medicinal product vocabulary**

Other

RxNorm

CVX

## **Quality of life measurements**

Not Captured

# **Lifestyle factors**

Captured

# **Lifestyle factors**

Other

# **Sociodemographic information**

Captured

## Sociodemographic information collected

Gender

# Quantitative descriptors

# Population Qualitative Data

# Population age groups

Paediatric Population (< 18 years)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Elderly (≥ 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Description of the population covered by the data source in the catchment area whose data are not collected (e.g., people who are registered only for private care)

General population

# Family linkage

Family linkage available in the data source permanently or can be created on an ad hoc basis

Ad hoc

# **Population**

**Population size** 

2700440

# **Active population size**

1218036

# Population by age group

Ago group	Population	Active population
Age group	size	size

Paediatric Population (< 18 years)	355473	192851
Children (2 to < 12 years)	181022	103833
Adolescents (12 to < 18 years)	141268	76896
Adults (18 to < 46 years)	1108854	461283
Adults (46 to < 65 years)	649960	341036
Elderly (≥ 65 years)	586153	222866
Adults (65 to < 75 years)	260698	113974
Adults (75 to < 85 years)	190021	71905
Adults (85 years and over)	135434	36987

# Median observation time

Median time (years) between first and last available records for unique individuals captured in the data source

1523.00

Median time (years) between first and last available records for unique active individuals (alive and currently registered) capt 4296.00

# Data flows and management

# Access and validation

#### **Governance details**

Documents or webpages that describe the overall governance of the data source and processes and procedures for data capture and management, data quality check and validation results (governing data access or utilisation for research purposes).

https://www.pharmacoepi.org/resources/policies/guidelines-08027/

## **Biospecimen access**

Are biospecimens available in the data source (e.g., tissue samples)?

No

## Access to subject details

Can individual patients/practitioners/practices included in the data source be contacted?

No

## **Description of data collection**

Anonymized patient records collected from patient management software used by GPs and selected specialists to document patients' clinical records

# Event triggering registration

#### Event triggering registration of a person in the data source

Practice registration

#### Event triggering de-registration of a person in the data source

Death

**Emigration** 

Loss to follow up

Practice deregistration

#### Event triggering creation of a record in the data source

Physician encounter

# Data source linkage

## Linkage

Is the data source described created by the linkage of other data sources (prelinked data source) and/or can the data source be linked to other data source on an ad-hoc basis?

No

# Data management specifications that apply for the data source

#### **Data source refresh**

Yearly

## Informed consent for use of data for research

Not Required

# Possibility of data validation

Can validity of the data in the data source be verified (e.g., access to original medical charts)?

No

## **Data source preservation**

Are records preserved in the data source indefinitely?

Yes

## **Approval for publication**

Is an approval needed for publishing the results of a study using the data source?

No

#### Data source last refresh

01/04/2022

# Common Data Model (CDM) mapping

# **CDM** mapping

Has the data source been converted (ETL-ed) to a common data model?

Yes

# **CDM Mappings**

#### **CDM** name

OMOP

#### **CDM** website

https://www.ohdsi.org/Data-standardization/

#### **Data source ETL CDM version**

5.3.1

# **Data source ETL frequency**

12,00 months

#### **Data source ETL status**

Completed